We’ve been getting a lot of questions over the past few days about Seroquel. That usually means I need to put up a new post, especially in light of recent events.
Earlier this week, AstraZeneca (the manufacturer of Seroquel) agreed to pay $520 million to settle a federal inquiry into Seroquel marketing practices. As we have stated before, Seroquel is approved to treat schizophrenia and bipolar disorder. However, investigators and plaintiffs believe that AstraZeneca marketed the drug for myriad other unapproved uses, including depression, obsessive-compulsive disorder, dementia, and post-traumatic stress disorder.
There are no criminal charges associated with the deal. Giving credence to plaintiffs’ claims (aside from the credibility arising from the mere fact of a whopping large settlement), is that federal investigators got much of their information from AstraZeneca whistleblowers, drug sales rep, James Wetta (who had some involvement in the whistleblowing at Eli Lilly around 2003).
The deal comes at a time when such deals seem to be simply the cost of doing business. As just one example, Boston Scientific is in the midst of trying to settle with investigators for $296 million over the actions of a company it acquired, Guidant. Seroquel’s settlement pales in light of the fact that in 2009 alone, they made $4.9 billion in Seroquel sales. Isn’t that criminal?
Anyway—civil lawsuits are still continuing, but Plaintiffs are having a hard time of it. For more information, visit Drug Recall Lawyer Blog posts on Seroquel.